BioSpace News Archive

BridgeBio Pharma, Inc. and National Resilience, Inc. today announced a strategic collaboration to manufacture and advance BBP-812, an investigational adeno-associated virus (AAV) 9 gene therapy for Canavan disease, and BBP-631, an investigational AAV 5 gene therapy for congenital adrenal hyperplasia (CAH).

ImmPACT Bio USA , Inc. (“ImmPACT BIO”), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer and autoimmune diseases, today announced that it will participate at the 2023 Cell & Gene Meeting on the Mesa, being held October 10-12, 2023.

Dignitana announces that the Palmetto GBA Medicare Administrative Contractor has issued a Local Coverage Determination to provide coverage guidance for Scalp Cooling for the Prevention of Chemotherapy-Induced Alopecia.

Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced that it will present two posters at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting, which is being held October 13-16, 2023 in Vancouver, BC, Canada.

Vir Biotechnology, Inc. announced that the Biomedical Advanced Research and Development Authority, part of the U.S. Department of Health and Human Services’ Administration for Strategic Preparedness and Response, has awarded Vir approximately $50 million in new funding to advance the development of novel monoclonal antibody candidates and delivery solutions to widen the applicability of mAbs in COVID-19 and in pandemic preparedness and response.

Windtree Therapeutics, Inc. announced that Craig Fraser, President and Chief Executive Officer, will be presenting at the upcoming Dawson James Small Cap Growth Conference on October 12, 2023 in Jupiter, FL.

Centessa Pharmaceuticals plc announced the appointment of April Dovholuk and Ellie Im, MD to Centessa’s executive team as Senior Vice President of Development Operations and Senior Vice President of Clinical Development, Oncology, respectively.

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY) announced today the granting, through a provisional resolution proposal, of two aids within the Spanish research plan 2021-2023 for public-private collaboration projects: the DICTIONIS Project with a budget of 951,000 euros (€) and the MODERN Project with a budget of €1,328,594.

Galectin Therapeutics, Inc. today reported the positive outcome of its fourth data and safety monitoring board (DSMB) meeting for NAVIGATE, its seamless, adaptive, Phase 2b/3 study of belapectin in patients with portal hypertension caused by non-alcoholic steatohepatitis (NASH) liver cirrhosis.

STRATA Skin Sciences, Inc., a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, announced that the company will be participating in two medical conferences during October.